These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30228883)

  • 1. Use of checkpoint inhibitors in liver transplant recipients.
    Munker S; De Toni EN
    United European Gastroenterol J; 2018 Aug; 6(7):970-973. PubMed ID: 30228883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
    Aguirre LE; Guzman ME; Lopes G; Hurley J
    Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
    Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
    Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
    Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
    Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
    Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
    Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
    Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors in liver transplant: a case series.
    Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
    J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
    Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP
    Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study.
    Carroll RP; Boyer M; Gebski V; Hockley B; Johnston JK; Kireta S; Tan H; Taylor A; Wyburn K; Zalcberg JR
    Lancet Oncol; 2022 Aug; 23(8):1078-1086. PubMed ID: 35809595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
    Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
    Front Immunol; 2021; 12():653437. PubMed ID: 34349755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.
    Amjad W; Kotiah S; Gupta A; Morris M; Liu L; Thuluvath PJ
    J Clin Exp Hepatol; 2020; 10(2):185-187. PubMed ID: 32189935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
    Ho CM; Chen HL; Hu RH; Lee PH
    Ther Adv Med Oncol; 2019; 11():1758835919843463. PubMed ID: 31065295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
    Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
    Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.
    Gassmann D; Weiler S; Mertens JC; Reiner CS; Vrugt B; Nägeli M; Mangana J; Müllhaupt B; Jenni F; Misselwitz B
    Transplant Direct; 2018 Aug; 4(8):e376. PubMed ID: 30255136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
    Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
    Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.
    Van Meerhaeghe T; Murakami N; Le Moine A; Brouard S; Sprangers B; Degauque N
    Clin Kidney J; 2024 Apr; 17(4):sfae061. PubMed ID: 38606169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.